HC Wainwright Analysts Raise Earnings Estimates for Alphatec

Alphatec Holdings, Inc. (NASDAQ:ATEC) – HC Wainwright increased their Q3 2026 EPS estimates for shares of Alphatec in a report released on Wednesday, August 5th. HC Wainwright analyst S. Lee now anticipates that the medical technology company will post earnings per share of ($0.02) for the quarter, up from their previous forecast of ($0.06). HC Wainwright has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Alphatec’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Alphatec’s Q4 2026 earnings at $0.07 EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at $0.08 EPS, Q2 2027 earnings at $0.11 EPS, Q3 2027 earnings at $0.11 EPS, Q4 2027 earnings at $0.18 EPS, FY2028 earnings at $0.79 EPS and FY2029 earnings at $1.05 EPS.

Other equities research analysts have also recently issued reports about the company. BMO Capital Markets raised their price target on Alphatec from $11.00 to $12.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Wall Street Zen lowered Alphatec from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Piper Sandler restated an “overweight” rating and set a $14.00 target price (down from $25.00) on shares of Alphatec in a report on Wednesday, May 6th. Needham & Company LLC lowered their target price on Alphatec from $25.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Finally, UBS Group lifted their price target on Alphatec from $15.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.40.

Alphatec Stock Down 1.3%

Shares of ATEC opened at $9.37 on Wednesday. The company has a market capitalization of $1.45 billion, a P/E ratio of -13.20 and a beta of 0.85. The company has a debt-to-equity ratio of 40.35, a current ratio of 1.89 and a quick ratio of 1.07. Alphatec has a one year low of $6.82 and a one year high of $23.29. The business’s 50 day simple moving average is $8.87 and its 200-day simple moving average is $10.55.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Tuesday, August 4th. The medical technology company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. The firm had revenue of $213.51 million for the quarter, compared to analysts’ expectations of $211.26 million. Alphatec had a negative net margin of 13.49% and a negative return on equity of 6,752.24%. The company’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.02 earnings per share.

Insider Buying and Selling at Alphatec

In other news, Director Karen K. Mcginnis sold 6,050 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $8.01, for a total transaction of $48,460.50. Following the transaction, the director owned 94,671 shares of the company’s stock, valued at $758,314.71. This represents a 6.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Tyson Eliot Marshall sold 8,168 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total value of $78,821.20. Following the completion of the transaction, the general counsel owned 630,398 shares in the company, valued at approximately $6,083,340.70. This represents a 1.28% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Alphatec by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,005 shares of the medical technology company’s stock worth $750,000 after buying an additional 3,196 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Alphatec during the first quarter worth approximately $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Alphatec by 18.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 265,907 shares of the medical technology company’s stock valued at $2,696,000 after buying an additional 41,264 shares during the period. Quantbot Technologies LP acquired a new position in Alphatec in the second quarter valued at approximately $242,000. Finally, Invesco Ltd. boosted its stake in Alphatec by 455.0% in the second quarter. Invesco Ltd. now owns 282,212 shares of the medical technology company’s stock valued at $3,133,000 after acquiring an additional 231,367 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

More Alphatec News

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: HC Wainwright raised its Q3 2026 EPS forecast to a loss of $0.02 from a loss of $0.06 and increased its Q4 2026 estimate to $0.07 from $0.05. These revisions suggest better-than-expected near-term operating performance and could support the stock.
• Positive Sentiment: The analyst projects Alphatec will become profitable in 2027, with quarterly EPS estimates ranging from $0.08 to $0.18, followed by earnings of $0.79 per share in 2028 and $1.05 in 2029. The FY2029 forecast was raised from $1.00, reinforcing the longer-term earnings-growth case.
• Positive Sentiment: The $24 price target represents a significant premium to the stock’s recent trading level. Investors may view the target and continued Buy rating as evidence that HC Wainwright sees meaningful value in Alphatec’s medical-technology platform and path toward profitability.
• Neutral Sentiment: Alphatec’s latest reported quarter was solid, with revenue of $213.5 million, up 15.1% year over year and above analyst expectations, while EPS matched the $0.07 consensus estimate. However, the company remains unprofitable overall, with analysts expecting a full-year loss of $0.44 per share.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast to a loss of $0.29 from a loss of $0.28, lowered FY2027 EPS to $0.47 from $0.59, and cut FY2028 EPS to $0.79 from $0.88. These reductions indicate that the profitability ramp may be slower than previously expected.
• Negative Sentiment: The reported short-interest data shows zero shares and a zero-day days-to-cover ratio, but the figures appear unreliable and provide no meaningful indication of short-seller positioning.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.